



Annex B: Awards to PHE in 2018/19

Project title	Directorate	Income to PHE	Funding source	Lead organisation	Collaborators
PRECISION Study	HI	£161,250	Cancer Research UK	MD Anderson Cancer Center, Texas	PHE
Human papillomavirus vaccine uptake in Colombia	NIS	£24,480	Colombian Dept of Health, Science and Technology (Spain)	University of Antioquia in Medellin, Colombia	PHE
Vaccine evaluation against Mycobacterium bovis	NIS	£41,484	Biotechnology and Biological Sciences Research Council	University of Surrey	PHE
Head to head vaccine evaluation	NIS	£100,000	TuBerculosis Vaccine Initiative (TBVI)	TuBerculosis Vaccine Initiative (TBVI)	PHE
Tuberculosis model development and vaccine evaluation	NIS	£156,232	TuBerculosis Vaccine Initiative (TBVI)	TuBerculosis Vaccine Initiative (TBVI)	PHE
Baseline shale gas radon monitoring	HPMD	£93,500	Department for Business, Enterprise and Industrial Strategy	British Geological Survey	PHE
Management of Nuclear Decommissioning Authority epidemiology database assets and biological sample bank	HPMD	£660,000	Nuclear Decommissioning Authority	Nuclear Decommissioning Authority	PHE
Method development for endocrine disruptors metabolic disorders and non-genotoxic carcinogenicity	HPMD	£414,342	European Commission	Utrecht University	PHE and 11 other international project partners

Project title	Directorate	Income to PHE	Funding source	Lead organisation	Collaborators
Vaccine fermentation	NIS	£160,108	Department for Environment, Food and Rural Affairs	The Animal and Plant Health Agency	PHE
Evaluation of the in-vitro activity of a compound against vancomycin-resistant <i>Enterococcus faecium</i> and <i>E. faecalis</i>	NIS	£11,583	Commercial	PHE	
Accelerating and enhancing the mental health and dementia intelligence networks work programme	HI	£300,000	NHS England	PHE	
Utilising One Health approached to accelerate vaccines for Ebola and Lassa Fever	NIS	£118,268	Biotechnology and Biological Sciences Research Council	University of Cambridge	PHE
Positive control antibodies for a CCHF ELISA diagnostic kit	NIS	£47,789	Medical Research Council	Liverpool School of Tropical Medicine	PHE
Survey of healthcare workers knowledge and attitudes about antibiotics and antibiotic resistance	NIS	£22,000	European Centre for Disease Prevention and Control	PHE	
Activity of a compound against <i>Pseudomonas aeruginosa</i> and other extended-spectrum beta-lactamases	NIS	£38,000	Commercial	PHE	
Crimean-Congo Haemorrhagic Fever vaccine (CCHFVaccine)	NIS	£26,487	European Commission	Public Health Agency of Sweden	PHE and 9 other international project partners
Pneumococcal nasopharyngeal carriage in UK infants given a reduced	NIS	£49,760	Bill and Melinda Gates Foundation	University College London	PHE

Project title	Directorate	Income to PHE	Funding source	Lead organisation	Collaborators
priming schedule of 13 valent pneumococcal vaccine					
Nagasaki University visiting scientist	NIS	£70,000	Nagasaki University	PHE	
Solid formulation vaccine characterisation	NIS	£65,904	Commercial	PHE	
Evaluation of the invitro activity of a compound against multi-drug-resistant Gram-negative isolates	NIS	£28,218	Commercial	PHE	
Vaccine evaluations	NIS	£84,900	Biotechnology and Biological Sciences Research Council	University of Surrey	PHE
Hantavirus vaccine development	NIS	£2,000,000	Innovate UK	PHE	Liverpool School of Tropical Medicine
Biomarker Identification in Ebola Models	NIS	£1,717,450	United States Food and Drug Administration	PHE	6 project partners
Fourth analysis of the Nuclear Weapons Test Participant Study	HPMD	£120,636	Ministry of Defence	PHE	
Joint Action on Points of Entry	HPMD	£193,024	European Commission	University of Thessaly	PHE
Civil Nuclear Emergency Radiation Monitoring Review	HPMD	£31,270	Department for Business, Energy and Industrial Strategy	PHE	
Surveillance of Campylobacter on chickens	NIS	£266,687	Food Standards Agency	PHE	Agri-Food and Biosciences Institute Northern Ireland
Ebola Correlates of Protection	NIS	£477,736	United States Food and Drug Administration	PHE	University of Liverpool, Phillips University Marburg.

Project title	Directorate	Income to PHE	Funding source	Lead organisation	Collaborators
Efficacy of liposomal ciprofloxacin	NIS	£93,806	Defense Threat Reduction Agency	Defence Science and Technology Laboratory	PHE
Mutant selection study	NIS	£40,000	Commercial	PHE	
Mutant whole genome sequencing study	NIS	£46,563	Commercial	PHE	
Activity of developmental antibiotics against problem Enterobacteriaceae and Pseudomonas aeruginosa	NIS	£97,141	Commercial	PHE	
Test Candida performance evaluation	NIS	£19,967	Commercial	PHE	
Analysing antibody-mediated complement deposition as a potential correlate of protection for B. pertussis infection	NIS	£101,518	European Commission	Radboud University Medical Center	Periscope Consortium (19 international academic and Public Health groups including PHE)
Serological standards for vaccine development	NIS	£974,400	Innovate UK	National Institute for Biological Standards and Control	PHE
Testing antimicrobial series	NIS	£17,100	Commercial	PHE	
Multi-agency programme to up-skill healthcare professionals on physical activity within care	HI	£4,498,461	Sport England	PHE	Faculty of Sport and Exercise Medicine; Oxford University Hospital Trust; Exercise Works
Scientific Exchange with Finlay Vaccines Institute on the assessment of Bordetella pertussis vaccines.	NIS	£8,250	Foreign & Commonwealth Office	Finlay Vaccine Institute, Cuba	PHE
Feasibility study to develop the SHIELD database system to manage a national cohort for radiation epidemiology	HPMD	£10,000	Nuclear Decommissioning Authority	PHE	

Project title	Directorate	Income to PHE	Funding source	Lead organisation	Collaborators
Comparison of methodologies used to estimate foodborne disease	NIS	£28,000	Food Standards Agency	Quadram Institute	PHE
Support for Lassa Fever diagnostics and bio-engagement at the Federal Teaching Hospital Abakaliki, Nigeria	NIS	£100,000	Counter Proliferation and Arms Control Centre	Defence Science and Technology Laboratory.	PHE
An exploration of the diversity and level of surface expression among clinical meningococcal isolates	NIS	£152,000	Commercial	PHE	
Development of a novel vaccine to protect against Q fever epidemics	NIS	£361,772	Innovate UK	University of Oxford	PHE
Evaluation of an assay for detection of carbapenemases in multidrug-resistant Gram-negative bacteria	NIS	£14,851	Commercial	PHE	
How is cancer care best provided to patients in English prisons?	HI	£43,006	National Institute for Health Research	Kings College London	PHE and 5 other project partners
HealthShop: A UK consortium to develop and evaluate healthier food purchasing interventions and policies	HI	£0	Medical Research Council	University of Oxford	PHE
Modification of antibiotic series	NIS	£102,000	Commercial	Kings College London	PHE
Efficacy of a vaccine against an aerosol challenge of B. anthracis	NIS	£746,314	Commercial	PHE	
Red Cross Resilient Responder Programme Evaluation	HPMD	£35,000	British Red Cross	PHE	

Project title	Directorate	Income to PHE	Funding source	Lead organisation	Collaborators
Expression Systems: Dengue and Zika vaccine assessment	NIS	£170,076	Commercial	PHE	
Redevelopment of a promising vaccine candidate for Crimean-Congo Haemorrhagic fever virus into a vector	NIS	£31,800	Medical Research Council	The Jenner Institute, Oxford	PHE
Development of an effective vaccine against tuberculosis	NIS	£883,644	Charity	The Jenner Institute, Oxford	PHE
Clostridium difficile infection Transmission Modelling	NIS	£85,000	Commercial	University of Leeds	PHE
Coxiella efficacy studies	NIS	£172,734	Defence Science and Technology Laboratory	PHE	
Mycobacterial Growth Inhibition Assay	NIS	£8,000	NC3Rs	The Jenner Institute, Oxford	
AWE Epidemiology Database	HPMD	£30,000	Atomic Weapons Establishment	PHE	
Susceptibility and resistance of pathogens causing lower urinary tract infections	NIS	£32,000	Commercial	PHE	
The challenges of tuberculosis	NIS	£34,700	British Council - Newton Bhabha Fund	PHE	Indian Institute of Science Education and Research
Open Innovation for antimicrobial resistance	NIS	£5,200,000	National Institute for Health Research	NIHR	
Pathology review and analysis of samples from MERS Co-V Studies	NIS	£16,828	Defence Science and Technology Laboratory	PHE	
Mechanistic interrogation of mycobacterial and vaccine-induced immunity	NIS	£4,586,128	US National Institute of Health	Infectious Disease Research Institute, Seattle	PHE

Project title	Directorate	Income to PHE	Funding source	Lead organisation	Collaborators
Joint programme 2 nd round	NIS	£28,249	European Commission	The French Agency for Food, Environmental and Occupational Health & Safety	PHE & several other international programme partners
HPV Natural Infection Immunity	NIS	£55,443	British Medical Association	PHE	5 international partners
Proactive	NIS	£353,097	European Commission	Union Internationale Des Chemins De Fer (France)	PHE and 12 other international project partners
Population based, prospective cohort study of pneumococcal pneumonia in adults in the UK	NIS	£37,500	Commercial	PHE	

Abbreviations: HI – Health Improvement; HPMD – Health Protection & Medical Directorate; NIS – National Infection Service

2018/19 application success rate = 43% (65 from 151 applications submitted)